Exacerbation of Psoriatic Skin Lesion followed by TNF-alpha Antagonist Treatment.
10.4078/jkra.2010.17.2.200
- Author:
Ji Min OH
1
;
Eun Mi KOH
;
Hyungjin KIM
;
Jaejoon LEE
;
Joong Kyong AHN
;
Hoon Suk CHA
;
Joo Heung LEE
;
Kee Taek JANG
Author Information
1. Division of Rheumatology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea. emkoh@skku.edu
- Publication Type:Case Report
- Keywords:
Psoriasis;
TNF-alpha antagonists;
Ankylosing spondylitis
- MeSH:
Arthritis, Psoriatic;
Autoimmune Diseases;
Humans;
Etanercept;
Immunoglobulin G;
Interferons;
Leg;
Physical Examination;
Psoriasis;
Receptors, Tumor Necrosis Factor;
Skin;
Spondylitis, Ankylosing;
Tumor Necrosis Factor-alpha
- From:The Journal of the Korean Rheumatism Association
2010;17(2):200-204
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
TNF-alpha antagonists have been successfully utilized in the treatment of autoimmune diseases, including psoriasis and psoriatic arthritis. Paradoxically, new onset or exacerbation of psoriatic lesions during treatment with TNF-alpha antagonists have been reported. It has been postulated that TNF-alpha blockade may cause disruption in the balance between TNF-alpha and type 1 interferon (IFN)-alpha, which are the key players in the pathogenesis of psoriasis. We report a case of psoriasis exacerbation during TNF-alpha antagonist therapy in a 53-years-old man with ankylosing spondylitis. The patient has been treated with etanercept for 3 years and 7 months when he developed accelerated deterioration of psoriasis. His condition was previously under control solely by local treatment. Physical examination revealed vigorous desquamative lesions with silvery scale in both lower legs. Deterioration of psoriasis was attributed to etanercept therapy and was subsequently discontinued. Clinical improvement of psoriasis has been observed 2 months following cessation of etanercept.
